Galena Biopharma, Inc. (Galena) is a biopharmaceutical company. The Company is developing and commercializing oncology therapeutics that address medical needs across the spectrum of cancer care. Galena�s development portfolio ranges from mid- to late-stage clinical assets, including an immunotherapy program led by NeuVax (nelipepimut-S) was in an international, Phase III clinical trial as of December 8, 2014. The Company�s commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. Its other pipeline products include GALE-301 (Folate Binding Protein (FBP)) and GALE-401 (Anagrelide CR). GALE-301 is immunogenic and can stimulate cytotoxic T lymphocyte (CTLs) to recognize and destroy FBP-expressing cancer cells. GALE-401 contains the active ingredient anagrelide, the United States Food and Drug Administration FDA-approved product.